New cancer clinical trial: Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate

Published on: November 29, 2017 at 10:00AM
Conditions:   Prostate Cancer;   Castration-resistant Prostate Cancer;   Drug
Interventions:   Drug: Abiraterone Acetate;   Drug: Docetaxel
Sponsor:   West China Hospital
Not yet recruiting
http://ift.tt/2AipvnT